Iannelli Federica, Lombardi Rita, Milone Maria R, Pucci Biagio, De Rienzo Simona, Budillon Alfredo, Bruzzese Francesca
Experimental Pharmacology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale - IRCCS, 80131 Naples, Italy.
Mercogliano Oncology Research Center (CROM), Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale - IRCCS, 80131 Naples, Italy.
Recent Pat Anticancer Drug Discov. 2018;13(2):184-200. doi: 10.2174/1574892812666171129141211.
Modifications of lipid metabolism have been progressively accepted as a hallmark of tumor cells and in particular, an elevated lipogenesis has been described in various types of cancers.
Important or deregulated activity of the mevalonate pathway has been demonstrated in different tumors and a wide range of studies have suggested that tumor cells are more dependent on the unceasing availability of mevalonate pathway metabolites than their non-malignant complements.
This study provides an overview of the state of the art of statins treatment on human cancer.
In recent times, various actions have been proposed for statins in different physiological and pathological conditions beyond anti-inflammation and neuroprotection activity. Statins have been shown to act through mevalonate-dependent and -independent mechanisms able to affect several tissue functions and modulating specific signal transduction pathways that could account for statin pleiotropic effect. Based on their characteristics, statins represent ideal candidates for repositioning in cancer therapy.
In this review article, we provide an overview of the current preclinical and clinical status of statins as antitumor agents. In addition, we evaluated various patents that describe the role of mevalonate pathway inhibitors and methods to determine if cancer cells are sensitive to statins treatment.
脂质代谢的改变已逐渐被视为肿瘤细胞的一个标志，尤其是在各类癌症中均有报道称脂肪生成增加。
已证实在不同肿瘤中，甲羟戊酸途径存在重要或失调的活性，并且大量研究表明，与非恶性细胞相比，肿瘤细胞对甲羟戊酸途径代谢产物的持续可用性更为依赖。
本研究概述了他汀类药物治疗人类癌症的最新进展。
近年来，除抗炎和神经保护活性外，他汀类药物在不同生理和病理条件下还展现出多种作用。他汀类药物已被证明可通过依赖甲羟戊酸和不依赖甲羟戊酸的机制发挥作用，这些机制能够影响多种组织功能并调节特定的信号转导途径，这可能解释了他汀类药物的多效性作用。基于其特性，他汀类药物是癌症治疗重新定位的理想候选药物。
在这篇综述文章中，我们概述了他汀类药物作为抗肿瘤药物的当前临床前和临床状况。此外，我们评估了各种描述甲羟戊酸途径抑制剂作用以及确定癌细胞对他汀类药物治疗是否敏感的方法的专利。
